Immune and Inflammatory Indices in Peripheral Blood Predict Prognosis of Glioma and Correlate With Grades and Subtypes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1282 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-10-13

Study Completion Date

2023-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Our study considered the relevant immune and inflammatory indices, such as immunoglobulin kappa light chain, TNF, and CD4+ Helper T lymphocyte% in a multi-institutional study with a large patient cohort (n=1282) from the east, northeast, and southeast of China. Our study shed light on the association of peripheral immune system status with prognosis, tumor grade, and subtype of glioma, which can potentially benefit future diagnostic and prognostic processes of glioma given its noninvasive nature. Moreover, the preoperative inflammatory status can be leveraged for timely interventions to reverse the immunosuppressive status of cancer patients and enhance anti-tumour immunity of glioma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunophenotyping From Blood of Patients With Malignant Gliomas

NCT02022384

Anaplastic Astrocytoma Glioblastoma Multiforme

COMPLETED

Validation Study of a Serum-miRNA Signature in Glioma Patients.

NCT06178692

Biomarker

ACTIVE_NOT_RECRUITING

The Predictive Value of MRI for Adult-type Diffuse Gliomas

NCT06572592

Glioma

NOT_YET_RECRUITING

Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study

NCT04634188

Brain Tumor

COMPLETED

Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients

NCT01135875

Glioblastoma Multiforme Healthy Volunteers

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma Immune Suppression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

primary glioma patients

We collected the information of clinical characteristics, inflammatory factors and immune factors of patients with primary glioma.

Detection of Immune and Inflammatory Indices in Peripheral Blood

Intervention Type OTHER

We detected immune and inflammatory indices in peripheral blood at each patient's at first hospitalizatin from October 13th, 2006, to April 6th, 2022.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Detection of Immune and Inflammatory Indices in Peripheral Blood

We detected immune and inflammatory indices in peripheral blood at each patient's at first hospitalizatin from October 13th, 2006, to April 6th, 2022.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* glioma grading and classification histologically verified in a resection or biopsy specimen according to 2016 WHO criteria;
* age \> 18 years;
* primary malignant glioma;
* the duration of follow-up \> 3 months;
* available data of lymphocyte subsets, cytokines, immune proteins and immune complements measured at the patient's first hospitalization.

Exculsion Criteria:

* current infectious disease, hyperpyrexia, hematological disease, diabetes mellitus, serious heart disease, hypertension, metabolic syndrome, severe renal or hepatic dysfunction, other cancer, autoimmune disease, inflammatory disease, or medication usage related to an inflammatory condition;
* prior cancer-specific pretreatment, such as chemotherapy or radiotherapy;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No